Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma

Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma

Sorafenib is a first-line treatment for patients with advanced hepatocellular carcinoma (HCC). These patients may simultaneously receive anti-hepatitis B treatment if they are viremic. The <i>N-Acetylgalactosaminyltransferase 14</i> (<i>GALNT14</i>) gene can serve as a biomar...

Full description

Bibliographic Details
Main Authors: Kung-Hao Liang, Sung-Fang Chen, Yu-Hua Lin, Yu-De Chu, Yang-Hsiang Lin, Ming-Wei Lai, Chih-Lang Lin, Chau-Ting Yeh
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Biomedicines
Subjects:
drug-drug interactions
glycoproteome
targeted therapy
entecavir
hepatitis B
Online Access:https://www.mdpi.com/2227-9059/9/11/1539

Internet

https://www.mdpi.com/2227-9059/9/11/1539

Similar Items